Novo Nordisk Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. | Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines. | Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. | Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. | |
Founding Date | Founding Date 1923 | Founding Date 1995 | Founding Date 1980 | Founding Date 1987 |
Type | Type Public | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations Bagsværd, DK HQ Tirana, AL Boufarik, DZ Hydra, DZ Tizi Ouzou, DZ Buenos Aires, AR North Sydney, AU see more | Locations New Delhi, IN HQ | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more |
Employees | Employees 69,260 | Employees 14,2112% increase | Employees 25,200 | Employees 18,0006% increase |
Valuation ($) | Valuation ($) 599.3 b | Valuation ($) N/A | Valuation ($) 172.1 b | Valuation ($) 105.3 b |
Financial | ||||
Revenue (est.) | Revenue (est.) kr232.3b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $28.2b (FY, 2023) | Revenue (est.) $27.1b (FY, 2023) |
Cost of goods | Cost of goods kr30.8b (FY, 2023) | Cost of goods N/A | Cost of goods $8.5b (FY, 2023) | Cost of goods $6.5b (FY, 2023) |
Gross profit | Gross profit kr202b (FY, 2023) | Gross profit N/A | Gross profit $19.7b (FY, 2023) | Gross profit $20.6b (FY, 2023) |
Net income | Net income kr83.7b (FY, 2023) | Net income N/A | Net income $6.7b (FY, 2023) | Net income $5.6b (FY, 2023) |
Operating ⚠ | ||||
Countries | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries 35 (FY, 2021) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products 9 (FY, 2021) |